To improve the ethical model in Brazil, a critical evaluation must be performed to avoid a hasty and costly implementation. The mere adaptation of other countries' models is not sufficient.
The authors would like to thank Ms. Aline Barbosa for assisting with the preparation of the poster. • Establishment of partnerships with educational institutions, research centers or international institutions
All these mechanisms will contribute to the quality of the ethical review process and the system Introduce metrics reports on research quality
(Increase the awareness and standards on main ethical issues identified through inquiries)
• Transparency in the activities of ethics committees • Promotion of discussions which may provide documents or guidelines, strengthening the evaluation system
Record of research and disclosure of data is essential to improve access to new drugs, and for researchers to perform detailed analysis of all study data increasing the decision-making capacity of patients and health professionals Clear requirements for ethics review and ethics system definitions are already available in Australia, New Zealand, USA and UK.
Based on those requirements, we suggest a streamlined process to improve the efficacy and reduce duplicity and bureaucracy in the Brazilian ethics system (see Table 4 ).
•
•

Recommendations for a streamlined approach in Brazil
Different solutions were implemented in several countries in order to improve the processes for multicenter studies (see Table 3 ).
• 
METHODOLOGY
We retrieved and reviewed the guidelines and regulations regarding the submission and approval of clinical trials from the following countries (and their respective regulatory organizations, see Figure 1 ):
Details on their ethics systems and guiding principles were extracted and tabulated.
Additionally, a literature review was performed in Medline and SciELO databases using the mesh terms "ethics", "ethics system" and "multicenter study", among others. Articles discussing improvements in these countries were reviewed. Clinical trials can provide several benefits to the population, the health system, the scientific community and the local economy ( Table 1 ).
The introduction of the National Ethics Committee (CONEP) represented a breakthrough for clinical research in Brazil in ethical terms; however, adjustments of the ethics system are required.
Due to clinical research dynamics of multi center studies, Brazil has been missing opportunities to participate in clinical trials, mainly due to the bureaucratic processes involved and the excessive time required for a study to be initiated.
Multicenter studies have several advantages, such as the ability to recruit larger samples in an agile manner and using less resources recruitment. Also, multicenter studies can make research on rare diseases feasible, since they allow for samples that are representative of the conditions, increasing the external validity. To evaluate the ethics system, regulations and guidelines in selected countries in order to propose recommendations for a more streamlined approach in Brazil.
INTRODUCTION
METHODS:
Guidelines and regulations from Brazil, New Zealand, Australia, USA and UK were reviewed to evaluate the ethics system and available guiding principles for clinical trials. Additionally, a literature review was performed in Medline and SciELO databases using the mesh terms "ethics", "ethics system" and "multicenter study", among others.
RESULTS:
Clear requirements for ethics review and ethics system definitions are available in Australia, New Zealand, USA and UK. Based on those requirements, we suggest a streamline process to improve efficacy and reduce duplicity and bureaucracy in the Brazilian ethics system. Our proposal has four main recommendations: review of the responsibilities of local IRBs and national IRB, development of a new regulatory submission process for multicenter study, development of guidelines and certification of IRBs, and transparency of the metrics report on research quality from IRBs.
• •
RESULTS
Ethics Systems have different approaches worldwide (see Table 2 ).
Key features of ethics system:
Key features of ethics system
Supervision of reviews can be done through National IRBs, Ministry of Health, and others organizations Review can be centralized by only one institution (e.g. National IRB) or decentralized (the own institutional committee or regional committees perform the review Some countries have alternative, multicenter pathways to ensure the review by an ethics committee Regulatory efficiency without loss of ethical integrity is an important challenge to improve the feasibility of a study.
Although the development of a streamlined approach may represent a solution for multicenter studies, this will only be viable and sustainable after all bureaucratic processes are harmonized.
Such harmonization includes:
The framework of ethics evolved overtime in different countries in order to follow the new dynamics of clinical research, and as a result of the globalization, increase in sponsored trials and the expansion of multicenter studies. 
DISCUSSION
